Allarity Swaps $3M of Streeterville Debt for Senior Preferred, Gives Lender 33% of ATM Proceeds
ALLR is trading near its 52-week low of $0.769 (13% above the low).
Summary
Allarity exchanged $3 million of its Streeterville note for 3,000 senior Series B preferred shares paying 9%, and in return Streeterville gets 33% of any future ATM net proceeds plus veto rights over new debt, equity and asset sales. No cash was raised.
Key Events · Financing and Capital Events · ALLR
-
Debt Swapped for Senior Preferred
Allarity partitioned $3,000,000 from its $10,930,000 Streeterville A-1 Note and exchanged it for 3,000 Series B preferred shares with a $1,050 stated value, cutting the note balance to $7,930,000. The exchange closed November 16, 2026, with no cash proceeds.
-
9% Preferred Sits Ahead of Common
The Series B accrues a 9% annual return compounded daily (15% after default), ranks senior to common in liquidation, and is not convertible into common stock. The 3,000 shares carry an aggregate stated value of $3,150,000.
-
Lender Takes 33% of ATM Proceeds
The Side Letter lets Allarity sell stock under an ATM only if it pays Streeterville 33% of weekly net proceeds, applied to preferred redemption or note repayment at Streeterville's election. Streeterville can revoke the consent at any time, and a missed payment is an event of default.
-
Covenants Restrict Financing and Sales
While Series B is outstanding, Allarity cannot make restricted debt or equity issuances, pledge assets, do a reverse split outside a Nasdaq deficiency cure, or enter a Fundamental Transaction without majority holder consent.
Analysis · ALLR · Life Sciences
Allarity retired $3 million of the $10.93 million Streeterville note by issuing 3,000 Series B preferred shares with a $1,050 stated value — $3.15 million in senior claims that sit ahead of common stock in liquidation and pay a 9% annual return, payable in cash or more preferred. No cash changed hands, so this is a balance-sheet restructuring rather than new money. The real cost is in the Side Letter: Streeterville consented to future ATM sales only if it receives 33% of the weekly net proceeds, applied to preferred redemption or note repayment at its election, and it can revoke that consent at any time. For a company that disclosed substantial doubt about its ability to continue as a going concern in its November 13 10-Q, that is a heavy toll on the only equity financing channel it has left. The covenants also block new debt or equity issuance, asset pledges, reverse splits outside a Nasdaq deficiency cure, and any Fundamental Transaction without Streeterville's consent — effectively giving one lender a veto over most financing and sale paths. The concurrent Phase 2 stenoparib trial expansion is a genuine clinical positive, but it does not change the capital structure math.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALLR was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14M. The 52-week trading range was $0.77 to $1.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.